Dermatological Drugs Market Forecast 2017-2027

NEW YORK, Sept. 4, 2017 /PRNewswire/ --

Psoriasis, Skin Infection, Acne, Dermatitis, Humira, Stelara, Enbrel, Remicade, Taltz, Cosentyx, Cubicin, Canesten, Epiduo, Bepanthen, Elocon, Galderma, Johnson & Johnson, AbbVie, GSK, Pfizer, LEO Pharma


Read the full report: http://www.reportlinker.com/p05089827/Dermatological-Drugs-Market-Forecast.html



The revenue of the dermatological drugs market in 2016 is estimated at $25.65bn and is expected to grow at a CAGR of 4.5% in the first half of the forecast period. Psoriasis drugs accounted for the largest share of the market in 2016, this segment generated $9.23bn.

How this report will benefit you
Read on to discover how you can exploit the future business opportunities emerging in this sector.

In this brand new 295-page report you will receive 111 tables and 92 figures – all unavailable elsewhere.

The 295-page report provides clear detailed insight into the dermatological drugs market. Discover the key drivers and challenges affecting the market.

Report Scope

• Dermatological drugs market forecasts from 2017-2027

This report also breaks down the revenue forecast for the main submarkets:
• Psoriasis
• Skin Infections
• Acne
• Dermatitis

Analysis of the Psoriasis drugs market. Revenue forecasts to 2027 are provided for the following drugs:
• Humira
• Stelara
• Enbrel
• Remicade
• Taltz
• Otezla
• Cosentyx

Analysis of the Skin Infections drugs market. Revenue forecasts to 2027 are provided for the following drugs:
• Cubicin
• Zyvox
• Valtrex
• Canesten
• Lamisil
• Bactroban

Analysis of the Acne drugs market. Revenue forecasts to 2027 are provided for the following drugs:
• Solodyn
• Epiduo
• Claravis
• Aczone
• Differin
• Abscorical/Epirus
• Ziana
• Doryx

Analysis of the Dermatitis drugs market. Revenue forecasts to 2027 are provided for the following drugs:
• Bepanthen/Bepanthol
• Protopic
• Dermovate
• Elocon

This report provides individual revenue forecasts to 2027 for these regional and national markets:
• US
• Germany
• France
• UK
• Italy
• Spain
• Japan
• China
• Brazil
• Russia
• India
• Rest of World

• This report provides discussion on pipeline products in various stages of clinical trials and regulatory approval.

• Our study includes SWOT analysis and Porter's Five Force analysis of the dermatological drugs market.

Two interviews conducted by Visiongain with experts in the dermatological drugs market:
• Interview with Dr Michael Siegel, Vice President of Research Programs at National Psoriasis Foundation
• Interview with Guillaume Clement, Executive Vice President, Region EUROPE+, LEO Pharma

Our study discusses the selected leading companies that are the major players in the dermatological drugs market:
• Galderma (Nestle Skin Health S.A.)
• Johnson & Johnson
• AbbVie
• GlaxoSmithKline (GSK)
• Pfizer
• LEO Pharma

Our new report discusses issues and events affecting the dermatological drugs market:
• Highly fragmented and competitive market with significant variations in different geographic regions
• Changing political and regulatory landscape changing the prospects of future products and reimbursement opportunities
• Future paradigm-shifting pipeline products
• Patent expirations
• Launches of new drug categories
Read the full report: http://www.reportlinker.com/p05089827/Dermatological-Drugs-Market-Forecast.html

About Reportlinker
ReportLinker is an award-winning market research solution. Reportlinker finds and organizes the latest industry data so you get all the market research you need - instantly, in one place.

http://www.reportlinker.com


__________________________
Contact Clare: clare@reportlinker.com
US: (339)-368-6001
Intl: +1 339-368-6001

View original content:http://www.prnewswire.com/news-releases/dermatological-drugs-market-forecast-2017-2027-300513572.html

SOURCE Reportlinker